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backgrounds, abilities, and resources among citizens are 
needed and include modifying reimbursement and pricing 
mechanisms, diversifying research, and developing low-cost 
PM programs.  © 2015 S. Karger AG, Basel 
 Introduction 
 Since the mapping of the human genome in 2003, 
enormous progress has been made in understanding mo-
lecular and genetic pathways underpinning human health 
and disease. The acquisition of new knowledge coupled 
with rapid developments within genetic sequencing and 
testing as well as plummeting costs of new technologies 
continually improve our potential to provide better health 
care. Genetic and genomic information can be used to 
unveil disease predisposition and onset in individuals 
much earlier and more accurately than previously possi-
ble, and an increasing number of therapies will target dis-
ease-specific molecules and biological pathways, rather 
than simply treating the symptoms of diseases  [1] . The 
traditional one-size-fits-all approach to disease preven-
tion, diagnosis, and treatment, which has proved to be 
inefficient, expensive, and sometimes even hazardous, is 
expected to be progressively replaced by a more individu-
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 Abstract 
 Background: Personalized medicine (PM) aims to offer tai-
lored health care to individuals on the basis of their genetic 
profile. This paper explores the types of behaviors and prac-
tices that citizens are expected to adopt under PM, examines 
whether such expectations are realistic, and proposes strate-
gies that could support citizens in the adoption of these be-
haviors.  Methods: Recent reports from national and interna-
tional medical organizations and funders of PM are reviewed 
to investigate the types of behaviors and practices that citi-
zens are expected to adopt under PM. These behaviors are 
examined in light of the current knowledge regarding citi-
zen involvement in health care.  Results: Under PM, citizens 
are expected to be much more educated, proactive, and en-
gaged in their health care than under conventional medical 
models. Actualizing such behaviors and practices may, how-
ever, be difficult or even unattainable for some groups of 
citizens.  Conclusions: Educating citizens in PM, as proposed 
in the reports, is important but may not suffice for the adop-
tion of new behaviors and practices by a majority of citizens. 
Approaches taking into consideration the heterogeneity of 
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alized and tailor-made approach. This ‘personalization’ 
of health care has captured worldwide attention, with var-
ious strategies under development to facilitate its realiza-
tion. For instance, precision medicine aims to create a 
new taxonomy of diseases based on molecular biology 
with the objective to improve disease classification and 
inform health-care treatment and decisions  [2] . Stratified 
medicine aims to group patients based on their genetic 
risk of disease or response to therapy with the objective 
to offer treatment that specifically targets those groups 
 [3] . Personalized medicine (PM) aims to use information 
about an individual’s genotype to guide decisions regard-
ing the prevention, diagnosis, and treatment of diseases 
 [4] . These strategies work towards the common objective 
to provide ‘the right patient with the right drug at the 
right dose at the right time’  [5] .
 The production, integration, and use of genetic and 
genomic information in health care requires significant 
changes in the way such care is organized and provided 
to individuals. Recent reports discussing precision medi-
cine  [2] , stratified medicine  [3] , and PM  [6–9] have high-
lighted the roles and actions that relevant stakeholders of 
PM should undertake to enable a smooth integration of 
genetic and genomic information into health care and, 
thus, facilitate the transition to a tailor-made approach to 
medicine, which we hereafter refer to as personalized 
medicine (PM). These reports (published by national and 
international medical organizations and funders) provide 
practical recommendations to researchers, health-care 
professionals, policy makers, health authorities, and 
pharmaceutical companies. For instance, researchers are 
encouraged to develop data management infrastructures 
to handle the growing amount of data produced from ge-
netic sequencing, health-care suppliers are advised to re-
organize their clinical services to enable the integration of 
genetic and molecular information in the electronic 
health records of patients, and pharmaceutical compa-
nies are encouraged to identify and qualify a range of new 
biomarkers that predict clinical response  [9] . However, 
the successful integration of genetic and genomic infor-
mation into health care also depends upon the actions of 
another central group of stakeholders, namely citizens. 
While many of the reports emphasize the importance of 
citizen engagement in PM and propose strategies to edu-
cate and engage citizens regarding new medical develop-
ments, they do not systematically provide recommenda-
tions for what citizens could do to enhance the realization 
of PM but rather describe the behaviors and actions that 
are important for individuals to adopt. In this paper, we 
scrutinize the content of these reports to identify the spe-
cific behaviors and practices that are targeted, examine 
obstacles that could prohibit many citizens to adopt these 
behaviors, and propose strategies that may facilitate such 
adoption.
 Methods 
 In October 2013, we conducted an internet search using Google 
and the following search terms: [‘personalized medicine’] and/or 
[personalised medicine] and/or [‘stratified medicine’] and/or 
[‘precision medicine’] combined with [report] and [pdf] to iden-
tify publicly available reports discussing the realization of PM. Re-
ports from national and international medical organizations and 
funders published between January 2008 and October 2013, writ-
ten in English and providing recommendations for the adoption 
of PM, were selected. 
 The reports were reviewed using a qualitative content analysis 
method  [10] according to the following steps. First, the content in 
the reports that describes behaviors and/or practices of citizens 
and/or patients was identified, extracted, and compiled into a list 
of verbatim texts. Next, the substantive content of these texts was 
examined in order to code and categorize it according to the type 
of behavior and/or practice it describes. Then, the categories were 
further examined to identify overarching themes into which the 
specific types of behaviors and practices could be grouped. Each 
category of behavior and/or practice was then analyzed in light of 
current knowledge regarding citizen and/or patient involvement 
in health care to determine the extent to which citizens and/or pa-
tients may realistically adopt, wholly or partly, such behaviors and 
practices. Hurdles that may impede such adoption were identified 
and discussed, and potential strategies to overcome these challeng-
es were proposed. 
 Results 
 Eighteen publicly available reports were identified ( ta-
ble 1 )  [2, 3, 5–9, 11–21] . Importantly, these reports do not 
make a clear distinction regarding when expectations ap-
ply to citizens in general or to patients in particular. All 
the reports use the term ‘patient’ at least once to refer to 
the end users of PM. Eight reports either use the term 
‘citizen’ or a combination of ‘citizen’ and ‘patient’. For 
instance, some reports emphasize the importance of pa-
tients sharing their data for research purposes  [2, 6, 14] , 
while others refer to citizens when describing this type of 
activity  [7, 21] . Similarly, some reports mention that pa-
tients will be involved in the decision-making processes 
regarding treatment  [2, 6, 9, 21] , while other reports state 
that patients and citizens will be involved  [7, 21] . This 
may reflect that PM, due to its proactive nature, will pro-
gressively blur the patient/non-patient dichotomy that 
has characterized traditional health-care models. For the 
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purpose of our analysis, we use the term ‘citizen’ when 
referring to citizens and patients; many of the behaviors 
and practices described in the reports do not require that 
the end users of PM are patients when they endorse the 
expected behaviors and practices.
 Our review of the reports reveals that citizens are ex-
pected to adopt a range of new behaviors and practices in 
relation to their health care. These are grouped into three 
overarching themes as described below and summarized 
in  table 2 . 
 (1) Citizens Are Expected to Actively Engage in Their 
Health Care 
 Citizens are expected to increasingly participate in the 
decision-making process regarding prevention, diagno-
sis, and treatment  [2, 6, 7, 9, 13, 14, 21] . For instance, they 
may discuss information about their individual genetic 
risk predisposition with their health-care provider and 
contribute to the design of tailor-made prevention strate-
gies to reduce their risk of becoming ill  [7, 13, 14, 21] . One 
report mentions that they may also discuss the choice of 
genetic tests and therapeutic options  [9] . To ensure that 
prevention strategies are efficient, citizens may regularly 
enrich and update their personal health information, in-
cluding genetic risk predisposition information, through 
the use of technologies such as web-based interfaces, self-
tracking systems, personal health records, smart phone 
applications, and biofeedback systems  [6, 7, 9, 13, 14, 21] . 
They may decide to voluntarily share information about 
their genetic predisposition with their relatives in order 
to increase the possibility that their relatives also take nec-
essary measures to prevent disease onset  [7, 16] . Some 
reports foresee that groups of citizens will purchase ser-
vices from direct-to-consumer genetic testing companies 
and seek help from their public health-care services to 
interpret the results of genetic tests  [13–14] . Finally, one 
report assumes that citizens will endorse targeted treat-
ment strategies and understand that access to conven-
tional treatment may be restricted when no positive effect 
for the individual’s specific genetic profile is documented 
 [18] . 
 (2) Citizens Are Expected to Actively Contribute to the 
Research Endeavor 
 Citizens are expected to contribute many different 
types of data about themselves such as ‘-omics’ data and 
imaging, clinical, environmental, behavioral, and socio-
economic data  [2, 6, 7, 16, 17, 21] . To do so, citizens may 
 Table 1.  PM reports
Report title [Ref] Publisher Year of
publication
Priorities for Personalized Medicine [20] The President’s Council of Advisors on Science and 
Technology
2008
Public Health in an Era of Genome-Based and Personalised Medicine [12] PHG Foundation 2010
Medical Profiling and Online Medicine: The Ethics of ‘Personalised Health 
Care’ in a Consumer Age [13]
Nuffield Council on Bioethics 2010
Personalised Medicine: Opportunities and Challenges for European Health 
Care [19]
European Commission Health Research Directorate 2010
Toward Precision Medicine: Building a Knowledge Network of Biomedical 
Research and a New Taxonomy of Disease [2]
National Research Council of the National Academies 2011
The Case for Personalised Medicine [6] Personalized Medicine Coalition 2011
Signature Event Report: Mapping a Way Through the Double Helix [8] Cancer Quality Council of Ontario 2011
Next Steps in the Sequence [14] PHG Foundation 2011
Advancing Access to Personalized Medicine: A Comparative Assessment of 
European Reimbursement Systems [15]
Personalized Medicine Coalition 2011
Addressing Race and Genetics. Health Disparities in the Age of Personalized 
Medicine [17]
Science Progress 2011
European Perspectives in Personalised Medicine. Conference report [18] European Commission 2011
Personalised Medicine: Status Quo and Challenges [9] The European Association for Bioindustries 2012
Privacy and Progress in Whole Genome Sequencing [16] Presidential Commission for the Study of Bioethical Issues 2012
ESF Forward Look: Personalised Medicine for the European Citizen [7] European Science Foundation 2012
Realising the Potential of Stratified Medicine [3] The Academy of Medical Sciences 2013
Paving the Way for Personalized Medicine [5] U.S. Food and Drug Administration 2013
Use of ‘-omics’ Technologies in the Development of Personalised Medicine [11] European Commission 2013
Innovation and Patient Access to Personalised Medicine [21] European Alliance for Personalised Medicine 2013
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consent to participation in research projects, for instance 
population health surveys or biobank projects, or agree 
that their biological samples and data collected through 
clinical and research settings be used for future research 
 [2, 6, 7, 16, 17, 21] . Some reports mention that citizens 
may also take the initiative to share their personal health 
data through citizen-led initiatives and health social net-
works  [2, 5, 7] , as already practiced within some commu-
nities of patients and health-care users  [22–24] , and may 
contribute to the establishment of patient registries that 
are made available to the research community  [2, 13, 16, 
22–24] . One report emphasizes that contributions from 
citizens with rare genotypes and phenotypes are particu-
larly useful  [2] . Additionally, as stated in two reports, cit-
izens may take the initiative to report health data to pub-
lic health authorities in case of potential infection or con-
tamination in the community  [7, 13] . Finally, two reports 
mention that citizens may communicate with researchers 
about patient values, informing them of their expecta-
tions regarding the translation of research discoveries 
into clinical practice  [11, 18] . 
 (3) Citizens Are Expected to Actively Engage in the 
Design of PM 
 Citizens are expected to participate in the design of PM 
by discussing its development and contributing to setting 
up priorities. This may be achieved through participation 
in public debates and deliberations, for instance to dis-
cuss the use of new technologies in health care or policies 
for reimbursement of targeted treatments  [3, 7, 13, 14, 16, 
18, 19] . Some reports also describe expectations that citi-
zens may participate in corporations and advisory bodies 
and work in close cooperation with public health author-
ities and drug manufacturers  [5, 7, 8, 18, 21] , for instance 
to advocate for the development of targeted drugs  [5, 13] 
or participate in the choice and validation of new diag-
nostics and therapeutics  [5] . Citizens may also be in-
volved in the design and development of educational 
tools to inform diverse publics about genetics and PM  [8] . 
Examples of educational projects in which citizens play 
an active role are provided in some reports, such as the 
National Institute for Health and Care Excellence (NICE) 
project in the UK  [3] . Patient advocacy groups may be 
central drivers of citizen engagement  [2, 21] , and two re-
ports mention that strong public engagement from ethnic 
groups and minorities, which traditionally have been un-
derrepresented, is particularly important  [7, 21] . 
 Discussion 
 The data we reviewed reveal that citizens are expected 
to adopt a whole range of behaviors and practices consid-
ered to be critical for the realization of PM. Citizens are 
seen as proactive, engaged, educated, responsible, and 
contributing partners of PM. These knowledgeable, ratio-
nal, and resourceful citizens not only engage in healthful 
behaviors by following early prevention strategies, par-
ticipating in the decision-making process regarding their 
medical follow-up, and sharing their genetic information 
 Table 2. Behaviors and practices expected of citizens as described in the reports
Citizens engage in their own health care
orn Participate in the decision-making process regarding prevention, diagnosis, and treatment [2, 5 – 7, 9, 13, 14, 21] 
orn Use new technology to manage their health information (including genetic risk predisposition information) [6, 7, 9, 13, 14, 21]
orn Share their genetic risk predisposition information with family members [7, 16]
orn Purchase genetic services and health-care products online [13, 14]
orn Endorse targeted treatment strategies based on their genetic profile [18]
Citizens contribute to the research endeavor
orn Consent to research uses of their biological samples and health-related data [2, 6, 7, 16, 17, 21]
orn Participate in research projects [2, 6, 7, 16, 17, 21]
orn Join citizen-led and health social networks data-sharing initiatives [2, 5, 7]
orn Contribute to the establishment of patient registries [2, 13, 16, 22 – 24]
orn Report health data to public health authorities [7, 12]
orn Communicate with researchers about patient values [11, 18]
Citizens engage in the design of PM
orn Participate in public consultations and debates on PM [3, 7, 13, 14, 16, 18, 19] 
orn Collaborate with health professionals and drug manufacturers through involvement in patient advocacy groups, advisory boards 
and health technology assessment bodies [5, 7, 8, 13, 16, 18 – 21]
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with relatives and public health authorities, they also ac-
tively contribute to the development of PM by, for in-
stance, providing access to their health data, taking the 
initiative to produce more data to feed both their own 
health records and research databases, and participating 
in public debates to discuss the design and development 
of PM. Additionally, they actively seek to access more 
comprehensive information about their health by using 
the services of direct-to-consumer genetic testing compa-
nies and buying technological devices and applications to 
manage personal health information in real time.
 These new behaviors and practices represent a radical 
change in the role of citizens compared with the way citi-
zens traditionally have been involved in their health care. 
This change echoes recent developments which encour-
age a move away from the rather paternalistic model, un-
der which citizens are primarily passive recipients of 
health care, to a participatory model of health care under 
which citizens are responsible drivers of their health, con-
tributors to the health-care system, and partners sharing 
decisions with health-care providers  [25] . 
 Although PM offers the opportunity for citizens to be 
more proactive and engaged in their own health care, 
there are several challenges towards the realization of 
such citizen engagement as described below. 
 Challenges towards the Realization of Citizen 
Engagement in PM 
 Health Literacy 
 Citizens must have sufficient health literacy to be able 
to actively engage in their health care. However, such lit-
eracy is not widespread in the population. As an illustra-
tion, a recent comparative study on health literacy in 8 
European Union member states reports that nearly every 
second respondent has limited health literacy and that a 
majority of respondents find it easier to follow instruc-
tions from their health-care provider than to make their 
own decisions or judgments  [26] . Empirical data show 
that individuals who receive information about their per-
sonal genetic risk predisposition often fail to interpret it, 
either overestimating or minimizing it  [27] , and may pre-
fer more intuitive, experience-based types of evidence 
 [28] . The same individuals often do not change their life-
style  [29] , either because they do not understand the in-
formation provided, do not want to change their life style, 
cannot afford to change it, or because genetic counseling 
protocols fail to raise some groups’ awareness of risk pre-
disposition  [30] . Educational interventions developed to 
improve risk perception do not seem to influence the way 
people understand their genetic risk  [31] . The lack of 
health literacy is worrisome knowing that citizens are not 
always accompanied by professionals to interpret their 
genetic information. For instance, citizens who decide to 
order genetic tests through commercial companies may 
not be able to assess the validity and clinical utility of these 
tests and may make misguided health-related decisions. 
The recent US Food and Drug Administration’s  [32] ban 
on 23andme personal genetic tests demonstrates that
information produced through commercial genetic tests 
may not be reliable. 
 Technology Literacy 
 Citizens must also have sufficient technology literacy 
to be able to fully benefit from PM. However, groups of 
citizens, for instance the elderly, who are the heaviest us-
ers of health-care services, often do not have the necessary 
skills and abilities to use new technologies such as web-
based health platforms or self-tracking devices, or are re-
luctant to use them  [13] . Other groups, although more 
interested in technology, may not have access to it if the 
e-infrastructures are missing or if the technology is too 
expensive.
 Lack of Economic Resources 
 Interfacing regularly with health-care provider, pur-
chasing genetic tests, and endorsing the prescription of 
targeted therapies require economic resources that some 
groups may not have. This may be particularly true in 
countries where health care is funded through a variety of 
private insurers that can decide to restrict access to ge-
netic tests and targeted therapies if considered too expen-
sive or ‘investigational’  [21, 33] . Even in countries where 
health care is publicly funded, public payers may decide 
not to cover additional costs of targeted drugs and require 
that the patients cover such costs themselves. To illustrate 
our point, we refer to ongoing plans in the UK to modify 
pricing systems with the objective to increase prices for 
targeted drugs  [34] and allow drug producers to achieve 
sufficient return on investment  [35] . For the time being, 
it is still unclear who will cover potential additional costs 
related to the use of targeted drugs. 
 Other Barriers to Contribution 
 Citizen contribution to the research endeavor, for in-
stance through participation in research trials, may be 
impeded by traditional research practices. For instance, 
ethnic groups and minorities are often excluded from re-
search and deprived of the opportunity to contribute and 
benefit from medical progress  [17] . As an illustration, 9 
out of 10 genome-wide association studies are reported to 
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be conducted on populations of European descent, un-
veiled gene-disease correlations therefore primarily ap-
plying to Caucasians  [17] . Paradoxically, groups of popu-
lation who are given the opportunity to contribute to the 
scientific endeavor may not be willing to do so. For in-
stance, 44% of Europeans are not willing to provide per-
sonal information to a biobank, and 67% prefer being 
asked to consent to every new piece of research instead of 
consenting only once to a broad range of research uses 
 [36] .
 Finally, broad citizen engagement in the public debate 
may be difficult to realize in practice. Current initiatives 
to engage a variety of citizen groups – other than the white 
and educated – in the design of research and health care 
often fail to reach groups which are usually underrepre-
sented. As an illustration, a recent review of citizens’ ju-
ries – a frequently used tool for engaging citizens in health 
policy decision-making – demonstrates that even when 
the organizers intend to recruit juries that are representa-
tive of the community, such juries primarily gather the 
most privileged groups of populations and fail to engage 
less advantaged groups  [37] . 
 Numerous initiatives are currently being developed 
which may make it possible for groups of citizens to adopt 
the new behaviors and practices that are needed for the 
realization of PM. For instance, patient-activated social 
networks such as the ‘quantified self’  [38] network offer 
individuals the opportunity to use simple technological 
devices to take their own health measurements  [39] , dis-
ease-oriented social networks such as ‘Patients like me’ 
 [23] offer patients the opportunity to share experiences 
and even launch research projects  [39] , and participant-
centric initiatives in biomedical research enable research 
participants to actively engage in the research process 
 [40] . More and more citizens are taking the initiative to 
collect and gather medical information through the use 
of web-based technologies and participation in e-patient 
networks  [22–24] . However, a general concern is that the 
early adopters of PM may primarily be citizens who are 
resourceful, highly educated, and socioeconomically ad-
vantaged. Adopting new behaviors and practices may be 
much more challenging for those who have lower levels 
of education and fewer socioeconomic resources. Some 
of the reports we have reviewed acknowledge this chal-
lenge but propose few solutions to address it. Instead, the 
focus is put on the importance of educating citizens in PM 
 [2, 3, 7, 8, 13, 14, 16, 20, 21] . Citizen education, for in-
stance, encompasses introducing genetics and genomics 
in the educational program of students, developing web-
sites and television channels to inform citizens about ge-
netics and the use of genetic tests, and organizing public 
forums and debates. These strategies are of great impor-
tance but may not suffice to address the socioeconomic, 
cultural, and generational challenges we have described.
 In recognition of these challenges, we review below re-
cently proposed strategies which may enable larger 
groups of citizens to participate in PM. At first glance, 
some of these strategies may seem too expensive and re-
source-demanding to implement. However, the current 
resources of health-care systems are allocated inefficient-
ly  [41–43] . If such resources can be used in a more effi-
cient and coherent manner, implementing the strategies 
we describe may not be unrealistic or insurmountable. 
 Reach Out to Larger Groups of Population 
 Alliances may be developed with local media, commu-
nity representatives, and advocacy groups  [44] to reach 
out to groups that usually are underrepresented in re-
search and health care, such as low-income groups, ethnic 
minorities, and groups living in rural areas  [17] . These 
groups could be involved in the design of educational 
tools and interventions that they know will be useful to 
them  [30] . Similarly, research programs may be devel-
oped in close cooperation with local communities to in-
clude a wider variety of populations. For instance, clinical 
trials which focus on genetic variation instead of ‘race’
or ‘ethnicity’ could be designed  [17] . Community-based 
participatory research programs under which communi-
ties and researchers work together in all phases of re-
search may be particularly fruitful  [45] . 
 Rethink Financial Schemes 
 Approval and reimbursement processes may be mod-
ified to provide quicker access to genetic tests and tar-
geted treatments  [15] . For instance, patient outcome and 
risk-sharing models  [46] could be more systematically 
used to document the efficiency of biomarkers and com-
panion diagnostics rather than stringent clinical data 
 [47] . Limitations may also be put on the pricing of tar-
geted drugs  [35] . Such limitations, albeit controversial, 
can be more acceptable for pharmaceutical companies if 
financial incentives are offered, for instance through in-
ternationally financed funds  [48] , for the development of 
targeted drugs that benefit large numbers of people, such 
as drugs used for the treatment of infectious diseases and 
cancer  [49] .
 Develop Low-Cost Programs and Tools 
 Free or low-cost programs offering access to genetic 
tests and targeted therapies may be proposed to groups 
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that are susceptible of not being able to afford those or 
may not want to use them  [50] . Such programs may, for 
instance, consist of publicly funded annual health check 
including mapping of genetic risk predisposition and life-
style intervention provided free of charge  [51] . In general, 
low-cost solutions should be preferred to expensive solu-
tions. For instance, health-care providers may prioritize 
investment in wireless medicine, which is cheaper than 
traditional technology and offers the possibility to per-
form medical tests remotely and at reduced cost while 
simultaneously limiting the number of medical consulta-
tions  [13] .
 Develop Alternative Solutions 
 Extensive health and technology literacy among large 
groups of citizens may be difficult to achieve. Alternative 
solutions could be proposed to citizens who do not have 
the ability to assess their own health or use modern tech-
nology but may benefit from personalized strategies. For 
instance, personal accompaniment and counselling could 
be proposed to senior citizens. 
 Finally, systematically mapping disparities in the ac-
cess and use of genetic tests and targeted therapies and 
making the results publicly available may motivate chang-
es in policy in areas where disparities are the most striking 
 [50] . 
 One may question whether these strategies can guar-
antee that citizens will make the necessary efforts to adopt 
new behaviors and practices. Although no guarantee can 
ever be provided that people will behave in certain ways, 
investing in programs which target specific groups of 
populations may be the helping hand that is needed to 
motivate the adoption of new behaviors among specific 
groups. For instance, publicly funded programs which of-
fer genetic risk mapping and lifestyle intervention free of 
charge have proved to increase the participation rate of 
high-risk patients in prevention programs while simulta-
neously potentially reducing future treatment costs  [51] .
 Conclusion 
 The reports we have reviewed envision citizens as ed-
ucated, engaged, resourceful, and responsible partners 
rather than passive recipients of health care. This new role 
of citizens offers exciting opportunities but requires levels 
of health and technology literacy as well as socioeconom-
ic resources that some groups of citizens may not have. 
Although some of the reports acknowledge that educa-
tional, technological, and socioeconomic hurdles may be 
encountered, they primarily focus on the importance of 
educating citizens in PM and propose few other solutions 
to address such challenges. Education in PM is critical. 
However, we suggest that the promoters of PM take into 
greater consideration the heterogeneity of citizens and 
develop policies and programs which specifically address 
the needs of the less educated and resourceful citizens. In 
Europe, discussions are currently taking place to reduce 
inequalities in access to PM  [21] . Such discussions should 
particularly be encouraged in countries where health is 
financed by a variety of private actors and individual ac-
cess to PM may be depending on the socioeconomic re-
sources of each individual. Citizens will be more receptive 
to adopting new behaviors and practices and contribute 
to the realization of PM only if educational, socioeco-
nomic, cultural, and generational hurdles are properly 
addressed. 
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